SQ109 (Synonyms: NSC 722041;SQ-109;SQ 109) |
Catalog No.GC12722
One-Click Copy Product Info
|
SQ109 is a novel, ampicillin-type, Mycobacterium tuberculosis cell wall synthesis inhibitor that effectively inhibits the growth of Mycobacterium tuberculosis (Mtb) by interfering with the biosynthesis of mycolic acid and other cell wall components.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 502487-67-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SQ109 is a novel, ampicillin-type, Mycobacterium tuberculosis cell wall synthesis inhibitor that effectively inhibits the growth of Mycobacterium tuberculosis (Mtb) by interfering with the biosynthesis of mycolic acid and other cell wall components[1, 2]. SQ109 is a synthetic, small-molecule, diamine-type anti-tuberculosis drug that targets and inhibits Mycobacterium membrane protein L3 (MmpL3), making it useful for treating drug-resistant tuberculosis[3]. SQ109 effectively inhibits the growth of the parasitic protozoan Trypanosoma brucei, killing the cells with an IC50 value of 50±8nM[4].
In vitro, treatment of Leishmania donovani-infected macrophages with SQ109 (0-10μM) for 48h inhibited the proliferation of L. donovani parasites in a dose-dependent manner[5]. Treatment of M. tuberculosis with SQ109 (10, 20μM) for 5 and 10 days, respectively, reduced the bacterial colony count by 1 and 2 log10 units[6].
In vivo, intraperitoneal injection of SQ109 (30, 100mg/kg/day) for 5 days in mice infected with Leishmania parasites significantly reduced the parasite burden in the blood and prolonged mouse survival; however, the parasite burden in the blood increased rapidly after treatment cessation[7].
References:
[1] Tahlan K, Wilson R, Kastrinsky D B, et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis[J]. Antimicrobial agents and chemotherapy, 2012, 56(4): 1797-1809.
[2] Sacksteder K A, Protopopova M, Barry C E, et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action[J]. Future microbiology, 2012, 7(7): 823-837.
[3] Li K, Schurig-Briccio L A, Feng X, et al. Multitarget drug discovery for tuberculosis and other infectious diseases[J]. Journal of medicinal chemistry, 2014, 57(7): 3126-3139.
[4] Veiga-Santos P, Li K, Lameira L, et al. SQ109, a new drug lead for Chagas disease[J]. Antimicrobial agents and chemotherapy, 2015, 59(4): 1950-1961.
[5] Gil Z, Martinez-Sotillo N, Pinto-Martinez A, et al. SQ109 inhibits proliferation of Leishmania donovani by disruption of intracellular Ca2+ homeostasis, collapsing the mitochondrial electrochemical potential (Δ Ψ m) and affecting acidocalcisomes[J]. Parasitology research, 2020, 119(2): 649-657.
[6] Zheng H, Williams J T, Coulson G B, et al. HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter[J]. Antimicrobial agents and chemotherapy, 2018, 62(7): 10.1128/aac. 02459-17.
[7] Baek K H, Phan T N, Malwal S R, et al. In vivo efficacy of SQ109 against Leishmania donovani, Trypanosoma spp. and Toxoplasma gondii and in vitro activity of SQ109 metabolites[J]. Biomedicines, 2022, 10(3): 670.
| Cell experiment [1]: | |
Cell lines | J774 macrophages |
Preparation Method | J774 macrophages were placed simultaneously with L. donovani promastigotes over plastic coverslips inside a 24-well plate, using a ratio of 1:20 macrophages:parasites. After a 24-h incubation to ensure macrophage adhesion and parasite invasion, the wells were washed three times with PBS to remove any non-adherent macrophages and non-internalized parasites. Subsequently, DMEM medium with increasing concentrations of SQ109 (0-10μM) was added to the wells and cells were incubated for 48h, including the appropriate controls. Coverslips were washed with PBS, sealed with methanol, and stained with Giemsa. The percentage of infected cells was determined by light microscopy. |
Reaction Conditions | 0-10μM; 48h |
Applications | SQ109 inhibits the proliferation of promastigotes of L. donovani in a dose-dependent manner, a 100% inhibition of proliferation being observed at a concentration of 5μM and an almost complete inhibition of growth at a concentration of 2μM. |
| Animal experiment [2]: | |
Animal models | Female BALB/c mice |
Preparation Method | Mice were infected with T.b.brucei Lister 427 (4×104 cells) by i.p. injection. The mice were divided into groups, and drug treatment was performed for five consecutive days by starting from day 1 post-infection and administering 30mg/kg of pentamidine, or 30mg/kg of SQ109, or 100mg/kg of SQ109, respectively. Drugs were freshly prepared each day. All drugs were administered once daily for 5 days via the per os (p.o.) route. Parasitemia was evaluated daily for 2 weeks by blood collection from the mouse tail vein, and survival was monitored for 1 month. Mice showing impaired health status and/or with a parasite load of >108 cells per mL of blood were euthanized. |
Dosage form | 30, 100mg/kg; 5 days; p.o. |
Applications | SQ109 treated group (30mg/kg), the average day of survival was 8.6, which is 3.4 days of extended survival compared to the vehicle control. Increasing the dose of SQ109 to 100mg/kg showed a similar (3.6) average days of extended survival. |
References: | |
| Cas No. | 502487-67-4 | SDF | |
| Synonyms | NSC 722041;SQ-109;SQ 109 | ||
| Chemical Name | N'-(2-adamantyl)-N-[(2E)-3,7-dimethylocta-2,6-dienyl]ethane-1,2-diamine | ||
| Canonical SMILES | CC(=CCCC(=CCNCCNC1C2CC3CC(C2)CC1C3)C)C | ||
| Formula | C22H38N2 | M.Wt | 330.55 |
| Solubility | DMSO : ≥ 25 mg/mL (75.63 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0253 mL | 15.1263 mL | 30.2526 mL |
| 5 mM | 605.1 μL | 3.0253 mL | 6.0505 mL |
| 10 mM | 302.5 μL | 1.5126 mL | 3.0253 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)